Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Lu AA21004 in major depressive disorder
2008-001581-91Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Primary endpoint: Long-term safety and tolerability. Started May 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-001581-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001581-91.